NBC News

Endocyte's EC145 Meets Primary Endpoint in Phase 2 Study, Demonstrating 85 Percent (2.3 month) Improvement in Median Progression-Free Survival for Treatment of Platinum ...

- 260 Percent (4.0 Month) Increase in Median Progression-Free Survival in Folate Receptor Positive Patient Subgroup - Plan to File for Conditional Approval in Europe - Initiated Phase 3 PROCEED Trial ...
ascopubs.org

Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors

Probability of Metachronous Testicular Cancer in Patients With Biopsy-Proven Intratubular Germ Cell Neoplasia Depends on First-Time Treatment of Germ Cell Cancer EC145 was administered as a bolus ...
Purdue University

Endocyte announces positive results from a Phase II clinical study of EC145 in patients with advanced non-small cell lung cancer (NSCLC)

Data presented at the World Conference on Lung Cancer shows clinical benefit in a significant percentage of patients with advanced adenocarcinoma of the lung. WEST LAFAYETTE, Ind. - Endocyte Inc., a ...
NBC News

Endocyte Announces Intent to Seek Conditional Marketing Authorization in the European Union for Targeted Therapeutic EC145 and Companion Imaging Diagnostic EC20 for Platinum ...

WEST LAFAYETTE, Ind., April 26, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging ...
International Business Times

FDA Could Approve Endocyte's EC145 to Treat Ovarian Cancer in Women: Analyst

RBC Capital Markets said FDA could approve Endocyte Inc.'s (NASDAQ: ECYT) EC145 to treat women patients with platinum-resistant ovarian cancer. The brokerage said Endocyte, based on guidance from ...